Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a ...

Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...

Vertex’s non-opioid painkiller eased pain intensity after surgery in two phase 2 clinical trials, giving the company the proof-of-concept needed to advance to a pivotal study in the second half of ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.